Same Indication

Ipilimumab vs Mavorixafor

Ipilimumab vs Mavorixafor: Overview

This comparison examines the pharmacological differences between Ipilimumab and Mavorixafor.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days.

Chemical Properties

Type: Ipilimumab β€” Antibody; Mavorixafor β€” Small molecule.